8th and 9th February 2023 – First PRESTO COST Action CA21130

P2X receptors as therapeutic targets

Next 8th and 9th of February 2023 by Palazzo Trotti Mosti, Ferrara (Italy) the first Presto Cost action meeting. This meeting is based upon work from PRESTO COST Action CA21130, supported by COST (European Cooperation in Science and Technology).

Name Role
Elena ADINOLFI Action Chair and Grant Holder Scientific Representative
Pablo PELEGRIN Action Vice Chair
Alison GARTLAND Science Communication Coordinator and WG5 Leader
Mariusz WIECKOWSKI Grant Awarding Coordinator
Friedrich KOCH-NOLTE WG1 Leader
Beata SPERLAGH WG2 Leader
Ivana NOVAK Training School Coordinator
Luke TATTERSALL Social Media Manager
Elena DE MARCHI Grant Holder Manager
Local Organizing Committee
8th February 2023
Time Speaker Topic
9:00-9:15 Elena Adinolfi (IT)

Welcome address


Session 1: Chairs Friedrich Koch-Nolte (DE), Sahil Adriouch (FR)

9:15-9:30 Dariusz Gorecki (UK) P2X7 purinoceptor in the pathogenesis and treatment of muscular dystrophy
9:30-9:45 Samuel Fountain (UK) Targeting P2X3 and P2X4 in the cardiovascular and respiratory systems
9:45-10:00 Gennady Yegutkin (FI) ATP and adenosine metabolism in cancer and inflammation
10:00-10:15 Michele Zanoni (IT) How P2X receptors have contributed to our knowledge of glioblastoma pathophysiology
10:15-10:30 Mehmet Ugur (TR) A different look at the intracellular signalling mechanisms of P2X7 receptor
10:30-10:45 Maria Domercq (ES) Role of Irf5-P2X4 signaling pathway in myelin metabolism and in regeneration in multiple sclerosis
10:45-11:00 Coffee Break

Session 2: Chairs Francesco Di Virgilio (IT), Ivana Novak (DK)

11:00-11:15 Mariusz Wieckowski (PL) Mitochondria and P2X7– in health and disease
11:15-11:30 Roberta Rizzo (IT) Role of Herpesvirus proteins in the control of host immune response
11:30-11:45 Friedrich Koch-Nolte (DE) Targeting the P2X7 ion channel with functional nanobodies
11:45-12:00 Anna Marei Mann (DE) Modulating the function of P2X7-expressing cells with Adeno-associated viral vectors that display P2X7-specific nanobodies
12:00-12:15 Danijela Laketa (RS) Defining purinome in neuroinflammation during the course of experimental autoimmune encephalomyeltis
12:15-12:30 Katarzyna Roszek (PL) ATP-mediated signaling of mesenchymal stem cells and cancer cells – friend or foe?
12:30-12:45 Kübra Ustaömer (TR) Physiatrist view of PRESTO
12:45-13:00 Ana Maria Sebastião (PT) Neuromodulation by purines – from neurogenesis towards neuronal signalling and neuroprotection
13:00-14:00 Lunch
14:00-15:15 Chairs: Beata Sperlagh (HU), Cécile Delarasse (FR)

Session 1: Chairs Beata Sperlagh (HU), Cécile Delarasse (FR)

14:00-14:15 Cécile Delarasse (FR) Purinergic receptor P2X7 in animal models of neuroinflammation
14:15-14:30 Hana Zemkova (CZ) Role of the first transmembrane domain in trafficking, sensitization and dye uptake function of rat P2X7 receptor
14:30-14:45 Tobias Engel (IE) The ATP-gated P2X7 receptor as theranostic biomarker for epilepsy
14:45-15:00 Nadežda Nedeljković (RS) Neurobiology Lab at Faculty of Biology University of Belgrade – Who we are, what we do and how we can contribute to PRESTO?
15:00-15:15 Shai Berlin (IL) NMDARs— from structure function to novel therapeutics
15:15-15:30 Coffee Break
15:30-17:15 Chairs: Dariusz Gorecki (UK), Tobias Engel (IE)

Session 2: Chairs Dariusz Gorecki (UK), Tobias Engel (IE)

15:30-15:45 Beata Sperlagh (HU) P2X receptors in psychiatric disorders
15:45-16:00 Carlos Matute (ES) Roles of P2X4 and P2X7 in demyelination and remyelination
16:00-16:15 Todor Dudev (BG) Molecular modeling studies on the mechanism of lithium’s mode of action intrating bipolar disorder
16:15-16:30 Felipe Ortega (ES) Live imaging of Neural Stem Cells to study the role of purinergic signalling in their lineage progression
16:30-16:45 Marija Adzic (RS) Can Probenecid counter neuroinflammation? Drug repurposing in vitro study in rat culture astrocyte model
16:45-17:00 Jasmina Trojachanec Pavlovska (MK) From substance to new drugs: development of new drugs – Introduction to clinical trials
17:00-17:15 Milorad Dragic (RS) Cerebral Open-Flow Microperfusion – a novel in vivo technique for continuous measurement of substance transport across intact blood-brain barrier
17:15-19:00 MC meeting
20:30 SOCIAL DINNER at Cusina e Butega, Corso Porta Reno 28, Ferrara


9th February 2023
Time Speaker Topic
9:00-10:30 Session 1: Valérie Vouret-Craviari (FR), Elena De Marchi (IT)
9:00-9:15 Juan José Martinez (ES) P2X7 receptor as a diagnostic and pharmacological target for infections and metabolic diseases
9:15-9:30 Maria João Queiroz (PT) Synthesis of heterocyclic compounds with biological properties
9:30-9:45 Constantinos Athanassopoulos (EL) P2X receptors’ modulators: Are they promising for anticancer combination therapies?
9:45-10:00 Anna Pegoraro (IT) P2X7 activation and release of vesicles from tumour cells affecting metastasis
10:00-10:15 Sahil Adriouch (FR) AAV vectors coding for nanobody-based biologics targeting P2X7 and their evaluation in animal models of colitis, experimental encephalitis, or cancer
10:15-10:30 Ankita Agrawal (DK) P2X Receptors, A Clinical Biochemistry approach
10:30-10:45 Coffee Break
10:45-12:30 Session 2: Juan José Martinez (ES), Elena Adinolfi (IT)
10:45-11:00 Valérie Vouret-Craviari (FR) Activation of the eATP/P2RX7/NLRP3/IL18 axis to treat pulmonary diseases
11:00-11:15 Benedetta De Ponte Conti (CH) P2X7R mediated regulation of gut microbiota in cancer
11:15-11:30 Luke Tattersall (UK) The P2RX7B splice variant modulates osteosarcoma cell behaviour and metastatic properties
11:30-11:45 Ruth Murrell-Lagnado (UK) P2X4, lysosome function and drug discovery at other ion channel targets
11:45-12:00 Ivana Novak (DK) ATP signaling in pancreatic cancer: the P2X7 receptor
12:00-12:15 Joel Arrais (PT) Artificial Intelligence for the targeted generation of novel compounds
12:15-12:30 Ines Zidi (TN) P2XR in inflammation and cancer
12:30-13:30 Lunch

Session 1: Chairs Luca Antonioli (IT), Pablo Pelegrin (ES)

13:30-13:45 Mark Young (UK) The molecular determinants of antagonist binding at P2X receptors
13:45-14:00 Annette Nicke (DE) Biochemical and functional analysis of P2X7 receptor signaling
14:00-14:15 Christa Müller (DE) Tools and Drugs for P2X Receptors
14:15-14:30 Diego Dal Ben (IT) Molecular modeling tools for the design of novel P2X ligands
14:30-14:45 Vanessa D’Antongiovanni (IT) Anti-inflammatory effects of novel P2X4 receptor antagonists, NC-2600 and NP-1815-PX, in a murine model of colitis
14:45-15:00 Eric Boué-Grabot (FR) Unravelling cell-specific function of P2X4 receptors in the brain using novel transgenic knock-in mice
15:00-15:15 Coffee Break

Session 2: Chairs Diego Dal Ben (IT), Niklas Rye Jørgensen (DK)

15:15-15:30 Pablo Pelegrin (ES) Modulation of the NLRP3 inflammasome by P2X7 receptor, implications in inflammation
15:30-15:45 Petros Petrou (CY) ER stress-induced glycogen metabolism during myogenesis and the link with P2X receptor signaling
15:45-16:00 Elisa Tinelli (IT) Identification of CNS penetrant P2X7 blockers: from the HTS to a preclinical model
16:00-16:15 Sirje Rüütel Boudinot (EE) Validation of anti P2X4 monoclonal
16:15-16:30 Relja Suručić (BA) P2X receptors and cannabinoids’ pathophysiological intersections with possible therapeutic outcomes
16:30-16:45 Victoria Maneu (ES) P2X receptors in retinal neurodegenerative diseases: a window to brain degenerative diseases
16:45-17:00 Concluding remarks